Green tea extract hepatotoxicity: EGCG dose threshold and the EFSA limits

Green tea extract is one of the most-marketed catechol-rich supplements and one of the very small number with reproducible, well-characterised liver toxicity. The dose at which the toxicity emerges has been mapped, the susceptibility genetics have been partially identified, and the European Food Safety Authority issued a quantitative limit in 2018. Despite all of this, products on the US market continue to carry doses near or above the documented hepatotoxicity threshold.

The case series that opened the question

Beginning in 2003, the Spanish liver injury registry and the French pharmacovigilance system began publishing case reports of acute hepatitis temporally associated with concentrated green tea extract products, particularly the weight-loss product Exolise (PMID: 12937435).¹ The original cases showed a hepatocellular injury pattern with elevated transaminases, jaundice, and resolution upon withdrawal. The US Drug Induced Liver Injury Network (DILIN) prospective registry has since documented over 100 cases of green tea extract-induced liver injury (PMID: 28922679).²

The implicated compound: EGCG

The catechin epigallocatechin gallate (EGCG) is the principal active and the principal toxin. EGCG is metabolised via the same UGT and SULT phase II pathways that handle many drugs, and at high concentrations it depletes hepatic glutathione, generates oxidant stress, and causes mitochondrial dysfunction. A 2018 EFSA safety assessment reviewed 14 human studies, 17 animal studies, and the case-series database, concluding that doses above 800 mg/day EGCG taken as a supplement (rather than from brewed tea) were associated with statistically significant elevation of liver enzymes (PMID: 29632962).³

The fasted-state interaction

Toxicity is markedly worse with fasted-state dosing. A 2008 pharmacokinetic study showed that taking 800 mg EGCG on an empty stomach produced 3-fold higher plasma EGCG concentrations than the same dose taken with food (PMID: 18156439).⁴ The reported DILIN cases overwhelmingly involve fasted dosing — typically in weight-loss protocols. Brewed green tea, even consumed in large amounts, does not produce the same risk because the catechin concentration per serving is modest and is consumed across a meal-pattern day.

The DILIN HLA association

A 2018 genome-wide association study within the DILIN registry identified a strong association between HLA-B*35:01 and green tea extract hepatotoxicity (odds ratio 7.1), the first identified pharmacogenomic susceptibility marker for a botanical (PMID: 30403776).⁵ This allele frequency is roughly 6% in European-descent populations, providing one explanation for why most consumers tolerate green tea extract while a minority experience severe injury. No clinical testing for this allele is currently routine before supplementation.

The Minnesota Green Tea Trial outcome

The largest controlled trial of green tea extract — the Minnesota Green Tea Trial of 1,075 postmenopausal women given 1,300 mg/day catechins (843 mg EGCG) or placebo for 12 months — found ALT elevations greater than 5x upper limit of normal in 6.7% of the green tea arm versus 0.7% of placebo, with several cases of clinically significant hepatitis (PMID: 28854335).⁶ This is the largest controlled-trial confirmation of the case-series signal.

EFSA limit and 2026 practical advice

The EFSA 2018 opinion established a tolerable upper level of 800 mg/day EGCG from supplement sources, with a recommendation that supplements be taken with food and that consumers with liver disease, on hepatotoxic medications, or with prior idiosyncratic drug-liver injury avoid concentrated catechin supplements entirely. Many products on the US market provide 500–700 mg EGCG per serving with daily-dose label directions exceeding the EFSA threshold. A 2023 LiverTox analysis listed green tea extract as Category B (highly likely hepatotoxin) — the same category as anabolic steroids and amoxicillin-clavulanate (PMID: 31644259).⁷ Brewed green tea remains safe at typical consumption — the issue is concentrated extracts. Anyone using a green tea extract product should take it with food, not combine it with other hepatotoxic supplements such as concentrated turmeric or kava, and consider periodic liver enzyme monitoring during prolonged use.